Developing microRNA therapeutics.
Rarely a new research area has gotten such an overwhelming amount of attention as have microRNAs. Although several basic questions regarding their biological principles still remain to be answered, many specific characteristics of microRNAs in combination with compelling therapeutic efficacy data and a clear involvement in human disease have triggered the biotechnology community to start exploring the possibilities of viewing microRNAs as therapeutic entities. This review serves to provide some general insight into some of the current microRNAs targets, how one goes from the initial bench discovery to actually developing a therapeutically useful modality, and will briefly summarize the current patent landscape and the companies that have started to explore microRNAs as the next drug target.
miRagen Therapeutics, Inc, Boulder, CO 80301, USA. eva.vanrooij@miragentherapeutics.com
Eva
E
van Rooij
Angela L
AL
Purcell
Arthur A
AA
Levin
D000818:Animals; D035843:Biomedical Research / Q000639:trends*; D004195:Disease Models, Animal; D004345:Drug Industry; D006801:Humans; D035683:MicroRNAs; D010330:Patents as Topic; D013812:Therapeutics / Q000639:trends*
D035683:MicroRNAs